Hybridyne Imaging Technologies, Inc., and the U.S. Department of Energy's Brookhaven National Laboratory are among over 100 companies and technology innovators from across the nation and around the world that will compete for top honors at the WBT2010, March 16-17, in Arlington-DFW, Texas.
Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced its accelerated timetable for delivery of the world's first handheld, integrated optical biosensor.
One of the nation’s leading providers of eye care services has aggressively entered the Pittsburgh market with eight locations across Western PA.
Net Optics, Inc., the global leader in intelligent network access solutions, today announced three new solutions aimed at improving healthcare network performance and enabling healthcare’s digital future
Electro-Optical Sciences, Inc. (the "Company") (NASDAQ: MELA), announced today that it will be doing business under the name "MELA Sciences" to better reflect the Company's focus on early melanoma detection. The Company's shares will continue to be traded on the NASDAQ capital market under the ticker symbol "MELA."
BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, today announced the global launch of the iLase(TM) diode laser, the world's first personal laser for dentists and hygienists designed to perform a full-range of minimally invasive soft-tissue and hygiene procedures. The iLase is being introduced today at the Chicago Dental Society Midwinter Show at McCormick Place West in Chicago.
Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular Diagnostics.
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
Qioptiq, a global company which designs and manufactures photonic products and solutions, today announced that it has introduced a new and innovative intraoral camera with autofocus for the dental market.
Olympus, a precision technology leader designing and delivering innovative solutions in Medical and Surgical products among other core business areas, today introduced a 9.9-millimeter gastroscope that delivers HDTV image quality and Narrow Band Imaging (NBI). The new scope, the GIF-H180J model, is intended for upper gastrointestinal screening, diagnostic and therapeutic procedures. Its notable new feature, an auxiliary water channel, flushes away blood, mucus and other debris inside the upper gastrointestinal tract, helping to ensure a clear view at all times. Combined with the optional OFP Flushing pump, the GIF-H180J allows for faster, more convenient irrigation of the visual field.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.